SBIR: Amyloid-Beta and Tau/Glycosaminoglycan Dual Inhibitor for Alzheimer's Disease

Grants and Contracts Details

StatusActive
Effective start/end date9/1/228/31/23

Funding

  • Gismo Therapeutics Incorporated: $179,952.00